# Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

> **NCT05111743** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9261 (actual)

## Conditions studied

- Age-related Macular Degeneration (AMD)

## Interventions

- **DRUG:** Brolucizumab

## Key facts

- **NCT ID:** NCT05111743
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2020-12-18
- **Final completion:** 2020-12-18
- **Target enrollment:** 9261 (ACTUAL)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111743, "Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05111743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*